Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Synthesis and characterization of chimeric 2-5A-DNA oligonucleotides.

Player MR, Torrence PF.

Curr Protoc Nucleic Acid Chem. 2001 May;Chapter 4:Unit 4.4. doi: 10.1002/0471142700.nc0404s01.

PMID:
18428851
2.

Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.

Prichard MN, Keith KA, Johnson MP, Harden EA, McBrayer A, Luo M, Qiu S, Chattopadhyay D, Fan X, Torrence PF, Kern ER.

Antimicrob Agents Chemother. 2007 May;51(5):1795-803. Epub 2007 Feb 26.

3.

Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues.

Zhang X, Amer A, Fan X, Balzarini J, Neyts J, De Clercq E, Prichard M, Kern E, Torrence PF.

Bioorg Chem. 2007 Jun;35(3):221-32. Epub 2006 Dec 2.

4.

The Ugi reaction in the generation of new nucleosides as potential antiviral and antileishmanial agents.

Fan X, Zhang X, Bories C, Loiseau PM, Torrence PF.

Bioorg Chem. 2007 Apr;35(2):121-36. Epub 2006 Sep 25.

PMID:
16996561
5.

Delivery of 2-5A cargo into living cells using the Tat cell penetrating peptide: 2-5A-tat.

Zhou L, Thakur CS, Molinaro RJ, Paranjape JM, Hoppes R, Jeang KT, Silverman RH, Torrence PF.

Bioorg Med Chem. 2006 Dec 1;14(23):7862-74.

PMID:
16908165
6.

Structurally diverse 5-substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro.

Torrence PF, Fan X, Zhang X, Loiseau PM.

Bioorg Med Chem Lett. 2006 Oct 1;16(19):5047-51. Epub 2006 Aug 1.

PMID:
16879965
7.

Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure.

Fan X, Zhang X, Zhou L, Keith KA, Prichard MN, Kern ER, Torrence PF.

J Med Chem. 2006 Jul 13;49(14):4052-4.

8.

Assembling a smallpox biodefense by interrogating 5-substituted pyrimidine nucleoside chemical space.

Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF.

Antiviral Res. 2006 Sep;71(2-3):201-5. Epub 2006 May 19.

PMID:
16759713
9.

5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity.

Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF.

J Med Chem. 2006 Jun 1;49(11):3377-82.

10.

A pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity.

Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF.

Bioorg Med Chem Lett. 2006 Jun 15;16(12):3224-8. Epub 2006 Apr 5.

PMID:
16603351
11.

Evaluation of synthetic oligonucleotides as inhibitors of West Nile virus replication.

Torrence PF, Gupta N, Whitney C, Morrey JD.

Antiviral Res. 2006 Jun;70(2):60-5. Epub 2006 Feb 13.

PMID:
16540182
12.

Synthesis and antiviral activities of 1,2,3-triazole functionalized thymidines: 1,3-dipolar cycloaddition for efficient regioselective diversity generation.

Zhou L, Amer A, Korn M, Burda R, Balzarini J, De Clercq E, Kern ER, Torrence PF.

Antivir Chem Chemother. 2005;16(6):375-83.

PMID:
16331842
13.

Endowing RNase H-inactive antisense with catalytic activity: 2-5A-morphants.

Zhou L, Civitello ER, Gupta N, Silverman RH, Molinaro RJ, Anderson DE, Torrence PF.

Bioconjug Chem. 2005 Mar-Apr;16(2):383-90.

PMID:
15769093
14.

3-Deazaadenosine analogues of p5'A2'p5'A2'p5'A: synthesis, stereochemistry, and the roles of adenine ring nitrogen-3 in the interaction with RNase L.

Kalinichenko EN, Podkopaeva TL, Budko EV, Seela F, Dong B, Silverman R, Vepsäläinen J, Torrence PF, Mikhailopulo IA.

Bioorg Med Chem. 2004 Jul 1;12(13):3637-47.

PMID:
15186848
15.

RSV infections: developments in the search for new drugs.

Torrence PF.

Drug News Perspect. 2000 May;13(4):226-33.

PMID:
12937627
16.

The quest for an efficacious antiviral for respiratory syncytial virus.

Torrence PF, Powell LD.

Antivir Chem Chemother. 2002 Nov;13(6):325-44. Review.

PMID:
12718405
17.

Probing the activation site of ribonuclease L with new N6-substituted 2',5'-adenylate trimers.

Münch U, Chen L, Bayly SF, Torrence PF.

Bioorg Med Chem. 2003 May 1;11(9):2041-9.

PMID:
12670655
18.

Targeted therapy of respiratory syncytial virus in African green monkeys by intranasally administered 2-5A antisense.

Leaman DW, Longano FJ, Okicki JR, Soike KF, Torrence PF, Silverman RH, Cramer H.

Virology. 2002 Jan 5;292(1):70-7.

19.

2-5A-antisense chimeras: inhibitors of respiratory syncytial virus infection.

Torrence PF.

Curr Opin Mol Ther. 1999 Jun;1(3):307-15. Review.

PMID:
11713795
20.
21.

Chemistry and biochemistry of 2',5'-oligoadenylate-based antisense strategy.

Adah SA, Bayly SF, Cramer H, Silverman RH, Torrence PF.

Curr Med Chem. 2001 Aug;8(10):1189-212.

PMID:
11472236
22.

Synthesis and RNAse L binding and activation of a 2-5A-(5')-DNA-(3')-PNA chimera, a novel potential antisense molecule.

Verheijen JC, Chen L, Bayly SF, Torrence PF, van der Marel GA, van Boom JH.

Nucleosides Nucleotides Nucleic Acids. 2000 Oct-Dec;19(10-12):1821-30.

PMID:
11200276
23.

Convergent synthesis of ribonuclease L-active 2',5'-oligoadenylate-peptide nucleic acids.

Wang Z, Chen L, Bayly SF, Torrence PF.

Bioorg Med Chem Lett. 2000 Jun 19;10(12):1357-60.

PMID:
10890163
24.

Incorporation of a 4-hydroxy-N-acetylprolinol nucleotide analogue improves the 3'-exonuclease stability of 2'-5'-oligoadenylate-antisense conjugates.

Verheijen JC, van Roon AM, Meeuwenoord NJ, Stuivenberg HR, Bayly SF, Chen L, van der Marel GA, Torrence PF, van Boom JH.

Bioorg Med Chem Lett. 2000 Apr 17;10(8):801-4.

PMID:
10782690
25.

Fluorescence resonance energy transfer analysis of RNase L-catalyzed oligonucleotide cleavage.

Geselowitz DA, Cramer H, Wondrak EM, Player MR, Torrence PF.

Antisense Nucleic Acid Drug Dev. 2000 Feb;10(1):45-51.

PMID:
10726660
26.

2-Methyladenosine-Substituted 2',5'-oligoadenylates: conformations, 2-5A binding and catalytic activities with human ribonuclease L.

Kitade Y, Wakana M, Tsuboi T, Yatome C, Bayly SF, Player MR, Torrence PF.

Bioorg Med Chem Lett. 2000 Feb 21;10(4):329-31.

PMID:
10714492
27.

Selective RNA cleavage by isolated RNase L activated with 2-5A antisense chimeric oligonucleotides.

Silverman RH, Dong B, Maitra RK, Player MR, Torrence PF.

Methods Enzymol. 2000;313:522-33. No abstract available.

PMID:
10595377
28.

Using fluorescence resonance energy transfer (FRET) for measuring 2-5A analogues ability to activate RNase L.

Cramer H, Geselowitz DA, Torrence PF.

Nucleosides Nucleotides. 1999 Jun-Jul;18(6-7):1523-5.

PMID:
10474231
29.

2-5A-PNA complexes: a novel class of antisense compounds.

Verheijen JC, Bayly SF, Player MR, Torrence PF, van der Marel GA, van Boom JH.

Nucleosides Nucleotides. 1999 Jun-Jul;18(6-7):1485-6.

PMID:
10474229
30.

2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection.

Barnard DL, Sidwell RW, Xiao W, Player MR, Adah SA, Torrence PF.

Antiviral Res. 1999 Apr;41(3):119-34.

PMID:
10320045
31.
32.

2,5-oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L.

Verheijen JC, van der Marel GA, van Boom JH, Bayly SF, Player MR, Torrence PF.

Bioorg Med Chem. 1999 Mar;7(3):449-55.

PMID:
10220031
33.
34.

Targeting RNase L to human immunodeficiency virus RNA with 2-5A-antisense.

Player MR, Maitra RK, Silverman RH, Torrence PF.

Antivir Chem Chemother. 1998 May;9(3):225-31.

PMID:
9875401
35.

2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr/abl mRNA in chronic myelogenous leukemia cells.

Maran A, Waller CF, Paranjape JM, Li G, Xiao W, Zhang K, Kalaycio ME, Maitra RK, Lichtin AE, Brugger W, Torrence PF, Silverman RH.

Blood. 1998 Dec 1;92(11):4336-43.

36.

Ribonuclease L, a 2-5A-dependent enzyme: purification to homogeneity and assays for 2-5A binding and catalytic activity.

Player MR, Wondrak EM, Bayly SF, Torrence PF.

Methods. 1998 Jul;15(3):243-53.

PMID:
9735309
37.
38.

The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.

Player MR, Torrence PF.

Pharmacol Ther. 1998 May;78(2):55-113. Review.

PMID:
9623881
39.

Nuclease-resistant composite 2',5'-oligoadenylate-3', 5'-oligonucleotides for the targeted destruction of RNA: 2-5A-iso-antisense.

Xiao W, Li G, Player MR, Maitra RK, Waller CF, Silverman RH, Torrence PF.

J Med Chem. 1998 Apr 23;41(9):1531-9.

PMID:
9554886
40.

Dissection of the roles of adenine ring nitrogen (N-1) and exocyclic amino (N-6) moieties in the interaction of 2-5A with RNase L.

Player MR, Kalinichenko EN, Podkopaeva TL, Mikhailopulo IA, Seela F, Torrence PF.

Biochem Biophys Res Commun. 1998 Apr 17;245(2):430-4.

PMID:
9571169
41.

Methods for the characterization of phosphatase-stabilized 2-5A-antisense chimeras.

Player MR, Xiao W, Cramer H, Torrence PF.

Bioconjug Chem. 1998 Jan-Feb;9(1):137-42.

PMID:
9460557
42.

A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system.

Castelli JC, Hassel BA, Wood KA, Li XL, Amemiya K, Dalakas MC, Torrence PF, Youle RJ.

J Exp Med. 1997 Sep 15;186(6):967-72.

43.
44.

The solid-phase synthesis of 2'-5'-linked oligoriboadenylates containing 8-bromoadenine.

Lesiak KB, Uznanski B, Torrence PF.

Appl Biochem Biotechnol. 1997 Jul-Aug;67(1-2):33-44.

PMID:
9382489
45.

Recruiting the 2-5A system for antisense therapeutics.

Torrence PF, Xiao W, Li G, Cramer H, Player MR, Silverman RH.

Antisense Nucleic Acid Drug Dev. 1997 Jun;7(3):203-6. Review. No abstract available.

PMID:
9212911
46.
47.

Targeting RNA decay with 2',5' oligoadenylate-antisense in respiratory syncytial virus-infected cells.

Cirino NM, Li G, Xiao W, Torrence PF, Silverman RH.

Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1937-42.

48.

Efficient functionalization of 2',5'-oligoadenylates with sulfur.

Lesiak K, Torrence PF.

Bioconjug Chem. 1997 Mar-Apr;8(2):199-203.

PMID:
9095361
49.

Neighboring group catalysis in the design of nucleotide prodrugs.

Khamnei S, Torrence PF.

J Med Chem. 1996 Sep 27;39(20):4109-15.

PMID:
8831776
50.

Synthesis and characterization of composite nucleic acids containing 2', 5'-oligoriboadenylate linked to antisense DNA.

Xiao W, Player MR, Li G, Zhang W, Lesiak K, Torrence PF.

Antisense Nucleic Acid Drug Dev. 1996 Winter;6(4):247-58.

PMID:
9012860

Supplemental Content

Loading ...
Support Center